Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Renatus logo — Protect the world from cholesterol

Renatus

Protect the world from cholesterol

Founded 2021 Korea South Korea South 1 employees Pharmaceutical

General Information

Company Name Renatus
Founded Year 2021
Location Korea South Korea South +1
Employees 1
Industries Pharmaceutical
Social

Get notified when Renatus moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Renatus

Renatus is an early-stage biotech company with the slogan "Protect the world from cholesterol," founded in 2021. The company is dedicated to developing innovative therapies that directly target and reverse cellular cholesterol accumulation, a key hallmark of various age-related and metabolic diseases. Renatus's diverse pipeline encompasses a wide range of therapeutic areas, including chronic kidney disease, atherosclerosis, Alzheimer's disease, metabolic-associated steatohepatitis (MASH), and cancer. At the core of Renatus's approach is an advanced technology designed to selectively target excess cholesterol, particularly within lysosomes. This innovation tackles a critical challenge in cholesterol-targeting therapies, as traditional strategies often disrupt normal cholesterol functions, leading to significant adverse effects. Renatus's technology overcomes this limitation by precisely targeting and removing excess lysosomal cholesterol without disrupting cholesterol essential for normal cellular processes. Importantly, the removal of lysosomal cholesterol induces effects beyond simply lowering cholesterol levels, reprogramming key cellular pathways such as mitochondrial homeostasis, lipid synthesis and metabolism, inflammation regulation, and cell survival mechanisms. By addressing lysosomal cholesterol accumulation, Renatus's technology has the potential to improve cellular health, restore lipid metabolism, and transform the treatment landscape for diseases such as atherosclerosis, chronic kidney disease, Alzheimer's disease, and more. Renatus operates within the pharmaceutical industry and its headquarters' location is not specified. There is no available information on the last investment and investors.

Taxonomy: Biotech, Therapeutics, Chronic Kidney Disease, Atherosclerosis, Alzheimer's Disease, MASH, Cancer, Cellular Cholesterol Accumulation, Lysosomal Targeting Technology, Metabolic Diseases, Cellular Health, Lipid Metabolism, Inflammation Regulation, Mitochondrial Homeostasis, Cell Survival Mechanisms

No funding data available for Renatus yet.

Get notified when Renatus raises funding

FAQ About Renatus

Protect the world from cholesterol
Renatus was founded in 2021.
Renatus is headquartered in Korea South.
Renatus operates in the following industries: Pharmaceutical.
Renatus has approximately 1 employees.

We're actively collecting intelligence on Renatus.

Track Renatus to get notified

Don't just browse. Track.

Signal Tracker monitors Renatus and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy